TP53 and cancer: The former anticancer mechanism of TTD is consistent with the present study and is likely NR4A1-dependent; however, the latter mechanism seems to be an NR4A1-independent anticancer mechanism of TTD since NR4A1 is known to regulate the AMPKα/mTOR signaling pathway only in p53 wild-type cancer cells [7], indicating that NR4A1-dependent anticancer activity does not fully cover TTD-mediated anticancer mechanisms, but other pathways are also involved, as previously reported.